Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Manns, Michael P
Malek, Nisar P
Wirth, Thomas C
MetadataShow full item record
AbstractVaccination using DCs pulsed with tumor lysates or specific tumor-associated peptides has so far yielded limited clinical success for cancer treatment, due mainly to the low immunogenicity of tumor-associated antigens. In this study, we have identified intratumoral virus-induced inflammation as a precondition for effective antitumor DC vaccination in mice. Administration of a tumor-targeted DC vaccine during ongoing virus-induced tumor inflammation, a regimen referred to as oncolysis-assisted DC vaccination (ODC), elicited potent antitumoral CD8+ T cell responses. This potent effect was not replicated by TLR activation outside the context of viral infection. ODC-elicited immune responses mediated marked tumor regression and successful eradication of preestablished lung colonies, an essential prerequisite for potentially treating metastatic cancers. Unexpectedly, depletion of Tregs during ODC did not enhance therapeutic efficacy; rather, it abrogated antitumor cytotoxicity. This phenomenon could be attributed to a compensatory induction of myeloid-derived suppressor cells in Treg-depleted and thus vigorously inflamed tumors, which prevented ODC-mediated immune responses. Consequently, Tregs are not only general suppressors of immune responses, but are essential for the therapeutic success of multimodal and temporally fine-adjusted vaccination strategies. Our results highlight tumor-targeting, replication-competent viruses as attractive tools for eliciting effective antitumor responses upon DC vaccination.
CitationVirus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. 2011, 121 (7):2570-82 J. Clin. Invest.
AffiliationDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
The following license files are associated with this item:
- DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
- Authors: Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW
- Issue date: 2009 Oct
- Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
- Authors: Song S, Zhang K, You H, Wang J, Wang Z, Yan C, Liu F
- Issue date: 2010 Oct
- Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination.
- Authors: Samadi-Foroushani M, Vahabpour R, Memarnejadian A, Namdar A, Khamisabadi M, Sadat SM, Asgarian-Omran H, Azadmanesh K, Kokhaei P, Aghasadeghi MR, Hadjati J
- Issue date: 2011 Dec
- Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
- Authors: Yasuda T, Kamigaki T, Nakamura T, Imanishi T, Hayashi S, Kawasaki K, Takase S, Ajiki T, Kuroda Y
- Issue date: 2006 Dec
- Potential approaches for more successful dendritic cell-based immunotherapy.
- Authors: Chiang CL, Balint K, Coukos G, Kandalaft LE
- Issue date: 2015 Apr